Takayuki Niitsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takayuki Niitsu has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Kiyoharu Fukushima
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine
6 shared publications - Hiroshi Kida
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Centre, Toyonaka, Japan
5 shared publications Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan
4 shared publicationsHaruhiko Hirata
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan
3 shared publicationsKotaro Miyake
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan
3 shared publications- Shota Yamamoto
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison, Madison, USA.
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70674
Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC : A Case Report
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain. We report a patient with Stage IVA lung adenocarcinoma and a programmed death‐ligand 1 tumour proportion score of ≥ 75% who achieved a durable partial response to first‐line pembrolizumab. After isolated left supraclavicular nodal oligoprogression in 2020, he received salvage radiotherapy and remained off systemic treatment for almost 5 years. In late 2025, multiple new right lower lobe nodules and pleural‐based lesions appeared near the original primary site and enlarged on serial CT, prompting pembrolizumab rechallenge. CT in February 2026 showed a renewed partial response. This case suggests that rechallenge with pembrolizumab may remain reasonable at late relapse in carefully selected patients with durable initial benefit, limited progression controlled locally, a long treatment‐free interval, and good performance status.
- 14 July 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70674
Open AccessRenewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC : A Case Report
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain. We report a patient with Stage IVA lung adenocarcinoma and a programmed death‐ligand 1 tumour proportion score of ≥ 75% who achieved a durable partial response to first‐line pembrolizumab. After isolated left supraclavicular nodal oligoprogression in 2020, he received salvage radiotherapy and remained off systemic treatment for almost 5 years. In late 2025, multiple new right lower lobe nodules and pleural‐based lesions appeared near the original primary site and enlarged on serial CT, prompting pembrolizumab rechallenge. CT in February 2026 showed a renewed partial response. This case suggests that rechallenge with pembrolizumab may remain reasonable at late relapse in carefully selected patients with durable initial benefit, limited progression controlled locally, a long treatment‐free interval, and good performance status.
- Open Access
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 911-920
Comparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials
Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa
- 21 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 911-920
Open AccessComparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials
Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa
- Open Access
- 16 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12)
Endobronchial Watanabe Spigot for Acute Empyema With Bronchopleural Fistula: A Case Series
Empyema with bronchopleural fistula (BPF), defined by persistent air leak with pleural infection, undermines negative‐pressure drainage and often leads to highly invasive procedures such as fenestration. While endobronchial Watanabe spigots (EWSs) have mainly been used for postoperative or chronic fistulas, their role as an early intervention in acute infectious empyema with BPF remains uncertain. We report three consecutive frail patients with acute empyema and persistent air leak due to BPF treated using a prospectively predefined early EWS approach. After adequate drainage and antibiotics failed to seal the fistula, endobronchial occlusion was performed at the earliest bronchoscopic opportunity before considering fenestration. In all cases, EWS placement achieved complete cessation of air leak, allowed chest tube removal within 6–26 days and obviated fenestration. Diverse microbiology, including polymicrobial infection and nontuberculous mycobacteria, was controlled without observed device‐related infection or migration. Early EWS may offer a minimally invasive, fenestration‐sparing option in selected patients.
- 16 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12)
Open AccessEndobronchial Watanabe Spigot for Acute Empyema With Bronchopleural Fistula: A Case Series
Empyema with bronchopleural fistula (BPF), defined by persistent air leak with pleural infection, undermines negative‐pressure drainage and often leads to highly invasive procedures such as fenestration. While endobronchial Watanabe spigots (EWSs) have mainly been used for postoperative or chronic fistulas, their role as an early intervention in acute infectious empyema with BPF remains uncertain. We report three consecutive frail patients with acute empyema and persistent air leak due to BPF treated using a prospectively predefined early EWS approach. After adequate drainage and antibiotics failed to seal the fistula, endobronchial occlusion was performed at the earliest bronchoscopic opportunity before considering fenestration. In all cases, EWS placement achieved complete cessation of air leak, allowed chest tube removal within 6–26 days and obviated fenestration. Diverse microbiology, including polymicrobial infection and nontuberculous mycobacteria, was controlled without observed device‐related infection or migration. Early EWS may offer a minimally invasive, fenestration‐sparing option in selected patients.
- Open Access
- 9 October 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 11 (10) , 353
ILD-Slider: A Parameter-Efficient Model for Identifying Progressive Fibrosing Interstitial Lung Disease from Chest CT Slices
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) is a severe phenotype of Interstitial Lung Disease (ILD) with a poor prognosis, typically requiring prolonged clinical observation and multiple CT examinations for diagnosis. Such requirements delay early detection and treatment initiation. To enable earlier identification of PF-ILD, we propose ILD-Slider, a parameter-efficient and lightweight deep learning framework that enables accurate PF-ILD identification from a limited number of CT slices. ILD-Slider introduces anatomy-based position markers (PMs) to guide the selection of representative slices (RSs). A PM extractor, trained via a multi-class classification model, achieves high PM detection accuracy despite severe class imbalance by leveraging a peak slice mining (PSM)-based strategy. Using the PM extractor, we automatically select three, five, or nine RSs per case, substantially reducing computational cost while maintaining diagnostic accuracy. The selected RSs are then processed by a slice-level 3D Adapter (Slider) for PF-ILD identification. Experiments on 613 cases from The University of Osaka Hospital (UOH) and the National Hospital Organization Osaka Toneyama Medical Center (OTMC) demonstrate the effectiveness of ILD-Slider, achieving an AUPRC of 0.790 (AUROC 0.847) using only five automatically extracted RSs. ILD-Slider further validates the feasibility of diagnosing PF-ILD from non-contiguous slices, which is particularly valuable for real-world and public datasets where contiguous volumes are often unavailable. These results highlight ILD-Slider as a practical and efficient solution for early PF-ILD identification.
- 9 October 2025
- Published by MDPI AG in Journal of Imaging
- Vol. 11 (10) , 353
Open AccessILD-Slider: A Parameter-Efficient Model for Identifying Progressive Fibrosing Interstitial Lung Disease from Chest CT Slices
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) is a severe phenotype of Interstitial Lung Disease (ILD) with a poor prognosis, typically requiring prolonged clinical observation and multiple CT examinations for diagnosis. Such requirements delay early detection and treatment initiation. To enable earlier identification of PF-ILD, we propose ILD-Slider, a parameter-efficient and lightweight deep learning framework that enables accurate PF-ILD identification from a limited number of CT slices. ILD-Slider introduces anatomy-based position markers (PMs) to guide the selection of representative slices (RSs). A PM extractor, trained via a multi-class classification model, achieves high PM detection accuracy despite severe class imbalance by leveraging a peak slice mining (PSM)-based strategy. Using the PM extractor, we automatically select three, five, or nine RSs per case, substantially reducing computational cost while maintaining diagnostic accuracy. The selected RSs are then processed by a slice-level 3D Adapter (Slider) for PF-ILD identification. Experiments on 613 cases from The University of Osaka Hospital (UOH) and the National Hospital Organization Osaka Toneyama Medical Center (OTMC) demonstrate the effectiveness of ILD-Slider, achieving an AUPRC of 0.790 (AUROC 0.847) using only five automatically extracted RSs. ILD-Slider further validates the feasibility of diagnosing PF-ILD from non-contiguous slices, which is particularly valuable for real-world and public datasets where contiguous volumes are often unavailable. These results highlight ILD-Slider as a practical and efficient solution for early PF-ILD identification.
- Open Access
- 10 September 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108347
Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis
- 10 September 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108347
Open AccessEffectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis
- Open Access
- 28 July 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (1) , 79-91
Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases
Interstitial lung diseases (ILDs) encompass a diverse group of pulmonary disorders, with progressive fibrosis leading to poor prognosis. Here we aimed to identify key molecules involved in progressive fibrosis across various ILDs, using spatial transcriptomics (ST). ST analysis (Visium) was performed on lung cryobiopsy specimens from five patients with various ILDs. Two cases, rich in young fibrotic lesions, as defined by fibroblastic foci and destructive alveolar organization, were selected for spatial high‐dimensional weighted gene coexpression network analysis (hdWGCNA) to identify key gene networks with biological significance in active fibrosis. We utilized public single‐cell RNA sequencing datasets of various ILDs, performed enrichment analysis and trajectory‐based differential expression analysis, and quantified cell–cell communication to evaluate the involvement of the spatially extracted module in fibrosis. Immunohistochemical staining of the extracted molecules was performed. Using hdWGCNA, we identified a distinct gene module (the SM2 module) enriched in young fibrotic lesions. The SM2 module was characterized by distinct features of fibroblast activation that were represented across various lesions. Key hub genes within this module, including COL1A2 , COL3A1 , COL1A1 , and SPARC , formed a robust coexpression network. Immunohistochemical staining showed that SPARC, a component of the SM2 module, was highly expressed in young fibrotic lesions, but not in old scarring lesions, across various ILDs. To assess the prognostic significance of SPARC immunohistochemical expression, we extended our analysis to a cohort of 71 patients with unclassifiable ILDs (uILDs), a particularly heterogeneous subtype with unclear pathogenesis and limited treatment options. Higher SPARC levels in the upper, lower, or both lung lobes in uILD were significantly associated with poor overall survival. In summary, an integrated cross‐disease approach using ST revealed key gene expression patterns central to active fibrosis and successfully identified SPARC as a potentially beneficial prognostic marker. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 28 July 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (1) , 79-91
Open AccessSpatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases
Interstitial lung diseases (ILDs) encompass a diverse group of pulmonary disorders, with progressive fibrosis leading to poor prognosis. Here we aimed to identify key molecules involved in progressive fibrosis across various ILDs, using spatial transcriptomics (ST). ST analysis (Visium) was performed on lung cryobiopsy specimens from five patients with various ILDs. Two cases, rich in young fibrotic lesions, as defined by fibroblastic foci and destructive alveolar organization, were selected for spatial high‐dimensional weighted gene coexpression network analysis (hdWGCNA) to identify key gene networks with biological significance in active fibrosis. We utilized public single‐cell RNA sequencing datasets of various ILDs, performed enrichment analysis and trajectory‐based differential expression analysis, and quantified cell–cell communication to evaluate the involvement of the spatially extracted module in fibrosis. Immunohistochemical staining of the extracted molecules was performed. Using hdWGCNA, we identified a distinct gene module (the SM2 module) enriched in young fibrotic lesions. The SM2 module was characterized by distinct features of fibroblast activation that were represented across various lesions. Key hub genes within this module, including COL1A2 , COL3A1 , COL1A1 , and SPARC , formed a robust coexpression network. Immunohistochemical staining showed that SPARC, a component of the SM2 module, was highly expressed in young fibrotic lesions, but not in old scarring lesions, across various ILDs. To assess the prognostic significance of SPARC immunohistochemical expression, we extended our analysis to a cohort of 71 patients with unclassifiable ILDs (uILDs), a particularly heterogeneous subtype with unclear pathogenesis and limited treatment options. Higher SPARC levels in the upper, lower, or both lung lobes in uILD were significantly associated with poor overall survival. In summary, an integrated cross‐disease approach using ST revealed key gene expression patterns central to active fibrosis and successfully identified SPARC as a potentially beneficial prognostic marker. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 6 January 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-14
Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-analysis
Background Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient. Methods We searched on PubMed, CENTRAL, Embase, and Web of Science. We included randomized controlled trials with outcomes measuring mid-term mortality within 6 months, changes in forced expiratory volume in one second (FEV1), St. George’s Respiratory Questionnaire (SGRQ), six-minute walk distance (6MWD) from baseline, adverse event related to procedures, and long-term mortality within 5 years. Bayesian network meta-analysis was performed. The certainty was assessed by CINeMA. Results Twenty-five randomized controlled trials involving 4,283 patients were included, identifying seven types of procedures and standard of care. Mid-term mortality increased in LVRS and endobronchial valve (EBV) (LVRS, risk ratio [RR] 3.26, 95% CrI 1.98–6.21, low certainty; EBV, RR 2.06 95% CrI 1.07–4.36, moderate certainty). LVRS showed the largest improvements: change in FEV1 (187.2 mL, 95% CrI 166.4–209.6), 6MWD (42.2 m, 95% CrI 33.2–50.5), and SGRQ (− 13.29 points, 95% CrI − 27.25–0.75). Among bronchoscopic procedures, high efficacy was noted in EBV and endobronchial coil (EBC) for FEV1 changes (EBV, 111.8 mL, 95% CrI 92.2–136.2; EBC, 74.1 mL, 95% CrI 47.6–101.7). Pneumothorax increased in these two procedures (EBV, RR 12.75, 95% CrI 5.52–35.48; EBC, RR 4.95, 95% CrI 1.12–40.90). Conclusion LVRS offers high efficacies but is accompanied by increased mid-term mortality. EBV and EBC also showed effectiveness; however, they increased pneumothorax, and EBV slightly increased mortality. For accurate assessment, long-term survival data of BLVR are needed.
- 6 January 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-14
Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-analysis
Background Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient. Methods We searched on PubMed, CENTRAL, Embase, and Web of Science. We included randomized controlled trials with outcomes measuring mid-term mortality within 6 months, changes in forced expiratory volume in one second (FEV1), St. George’s Respiratory Questionnaire (SGRQ), six-minute walk distance (6MWD) from baseline, adverse event related to procedures, and long-term mortality within 5 years. Bayesian network meta-analysis was performed. The certainty was assessed by CINeMA. Results Twenty-five randomized controlled trials involving 4,283 patients were included, identifying seven types of procedures and standard of care. Mid-term mortality increased in LVRS and endobronchial valve (EBV) (LVRS, risk ratio [RR] 3.26, 95% CrI 1.98–6.21, low certainty; EBV, RR 2.06 95% CrI 1.07–4.36, moderate certainty). LVRS showed the largest improvements: change in FEV1 (187.2 mL, 95% CrI 166.4–209.6), 6MWD (42.2 m, 95% CrI 33.2–50.5), and SGRQ (− 13.29 points, 95% CrI − 27.25–0.75). Among bronchoscopic procedures, high efficacy was noted in EBV and endobronchial coil (EBC) for FEV1 changes (EBV, 111.8 mL, 95% CrI 92.2–136.2; EBC, 74.1 mL, 95% CrI 47.6–101.7). Pneumothorax increased in these two procedures (EBV, RR 12.75, 95% CrI 5.52–35.48; EBC, RR 4.95, 95% CrI 1.12–40.90). Conclusion LVRS offers high efficacies but is accompanied by increased mid-term mortality. EBV and EBC also showed effectiveness; however, they increased pneumothorax, and EBV slightly increased mortality. For accurate assessment, long-term survival data of BLVR are needed.
- Open Access
Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
Objective No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated the efficacy of antifibrotics in patients with PF-ILD. Methods We retrospectively reviewed the medical records of patients with ILD from January 2012 to July 2021. Patients were diagnosed with PF-ILD if they had ≥10% fibrosis on high-resolution CT (HRCT) and a relative forced vital capacity (FVC) decline of either ≥10% or >5% to Results Of the 574 patients, 167 were diagnosed with PF-ILD (idiopathic pulmonary fibrosis (IPF), n=64; non-IPF, n=103). Antifibrotics improved the FVC decline in both IPF (p=0.002) and non-IPF (p=0.05) (IPW: IPF, p=0.015; non-IPF, p=0.031). Among patients with IPF, OS was longer in the antifibrotic group (log-rank p=0.001). However, among patients with non-IPF, OS was not longer in the antifibrotic group (p=0.3263) (IPW and statistical matching: IPF, p=0.0534 and p=0.0018; non-IPF, p=0.5663 and p=0.5618). Conclusion This is the first real-world study to show that antifibrotics improve the FVC decline in PF-ILD. However, among patients with non-IPF, we found no significant difference in mortality between those with and without antifibrotics. Future studies must clarify whether antifibrotics improve the prognosis of non-IPF.
Open AccessReal-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
Objective No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated the efficacy of antifibrotics in patients with PF-ILD. Methods We retrospectively reviewed the medical records of patients with ILD from January 2012 to July 2021. Patients were diagnosed with PF-ILD if they had ≥10% fibrosis on high-resolution CT (HRCT) and a relative forced vital capacity (FVC) decline of either ≥10% or >5% to Results Of the 574 patients, 167 were diagnosed with PF-ILD (idiopathic pulmonary fibrosis (IPF), n=64; non-IPF, n=103). Antifibrotics improved the FVC decline in both IPF (p=0.002) and non-IPF (p=0.05) (IPW: IPF, p=0.015; non-IPF, p=0.031). Among patients with IPF, OS was longer in the antifibrotic group (log-rank p=0.001). However, among patients with non-IPF, OS was not longer in the antifibrotic group (p=0.3263) (IPW and statistical matching: IPF, p=0.0534 and p=0.0018; non-IPF, p=0.5663 and p=0.5618). Conclusion This is the first real-world study to show that antifibrotics improve the FVC decline in PF-ILD. However, among patients with non-IPF, we found no significant difference in mortality between those with and without antifibrotics. Future studies must clarify whether antifibrotics improve the prognosis of non-IPF.
- Open Access
- 23 May 2022
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 72 (5) , 005378
Mycobacterium senriense sp. nov., a slowly growing, non-scotochromogenic species, isolated from sputum of an elderly man
A slowly growing mycobacteria, identified as strain TY59T, was isolated from sputum of an elderly man with pneumonia. Sequencing of the 16S rRNA gene indicated that this strain was similar to members of the Mycobacterium avium complex and closely related species. Strain TY59T has highest 16S rRNA gene sequence similarities to the type strains of Mycobacterium colombiense (99.80 % sequence similarity), Mycobacterium vulneris (99.74 %), Mycobacterium timonense (99.54 %), Mycobacterium avium subsp. avium (99.54 %) and Mycobacterium avium subsp. silvaticum (99.54 %). Analysis of the internal transcribed spacer (ITS) and DNA-directed RNA polymerase subunit beta (rpoB) sequences gave similar results to the 16S rRNA gene analysis. The closest species to strain TY59T were M. colombiense and M. vulneris with 97.90–98.25 % identity in ITS and 96.4–96.6 % in rpoB. The strain's 65 kDa heat shock protein (hsp65) gene was different from those of M. vulneris , M. colombiense and M. avium subsp. silvaticum with 72.4–74.2 % identity. Average nucleotide identity results showed a 93.4 % match to M. vulneris as the maximum value. Phenotypically, the non-chromogenicity, rough colonies, growth at 42 °C, negative results for nitrate reduction, β-glucosidase and Tween 80 hydrolysis, and positive results for catalase activity set this strain apart from closely related species. We propose that Mycobacterium senriense sp. nov. is a novel species of slowly growing mycobacteria. The type strain is TY59T (RIMD 1371001T=CIP 111917T).
- 23 May 2022
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 72 (5) , 005378
Open AccessMycobacterium senriense sp. nov., a slowly growing, non-scotochromogenic species, isolated from sputum of an elderly man
A slowly growing mycobacteria, identified as strain TY59T, was isolated from sputum of an elderly man with pneumonia. Sequencing of the 16S rRNA gene indicated that this strain was similar to members of the Mycobacterium avium complex and closely related species. Strain TY59T has highest 16S rRNA gene sequence similarities to the type strains of Mycobacterium colombiense (99.80 % sequence similarity), Mycobacterium vulneris (99.74 %), Mycobacterium timonense (99.54 %), Mycobacterium avium subsp. avium (99.54 %) and Mycobacterium avium subsp. silvaticum (99.54 %). Analysis of the internal transcribed spacer (ITS) and DNA-directed RNA polymerase subunit beta (rpoB) sequences gave similar results to the 16S rRNA gene analysis. The closest species to strain TY59T were M. colombiense and M. vulneris with 97.90–98.25 % identity in ITS and 96.4–96.6 % in rpoB. The strain's 65 kDa heat shock protein (hsp65) gene was different from those of M. vulneris , M. colombiense and M. avium subsp. silvaticum with 72.4–74.2 % identity. Average nucleotide identity results showed a 93.4 % match to M. vulneris as the maximum value. Phenotypically, the non-chromogenicity, rough colonies, growth at 42 °C, negative results for nitrate reduction, β-glucosidase and Tween 80 hydrolysis, and positive results for catalase activity set this strain apart from closely related species. We propose that Mycobacterium senriense sp. nov. is a novel species of slowly growing mycobacteria. The type strain is TY59T (RIMD 1371001T=CIP 111917T).